🏢 官网IRANNXCodex · 实盘不做把握 2/10
北京时间·🕒 发布 04:05:27时区推断·⟳ 抓取 04:07:15回填·⚡ 决策 07-17 04:08:11·102.8 天前
Annexon向两名新入职非高管员工授予纳斯达克规则下的入职激励期权
这是公司按 Nasdaq Listing Rule 5635(c)(4) 披露的常规员工入职激励期权，属于薪酬/合规公告，不改变 Annexon（ANNX.US）的药物管线、收入、现金流或临床里程碑预期。
📄 原文ANNX↗ 原文
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Skip to main navigation with us together we’re making a difference News Release Details Annexon Reports Inducement Gran…
不做 Annexon（ANNX.US）
例行入职激励期权授予公告，不涉及临床、监管、订单、融资或业绩增量，无法形成同向可交易 edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-16 · 扩散 low · price-in 风险 low ↗
关键理由
- 这是公司按 Nasdaq Listing Rule 5635(c)(4) 披露的常规员工入职激励期权，属于薪酬/合规公告，不改变 Annexon（ANNX.US）的药物管线、收入、现金流或临床里程碑预期。
主要风险
- 若后续另有临床数据、监管进展或融资公告，需要作为新事件单独研判；本公告本身不构成交易催化。
原文全文
展开原文 · 2,548 字
Skip to main navigation
with us
together we’re making a difference
News Release Details
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026 at 4:05 PM EDT
PDF Version
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $6.50, which was the closing price of Annexon’s common stock on July 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Print
IR Contact
RSS Feeds
Email Alerts
Contact Us
info@annexonbio.com
650.822.5500
Investors:
investors@annexonbio.com
Media:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
Annexon Biosciences
1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005
Privacy Policy
Terms of Use
© 2026 Annexon Inc. All rights reserved.
This website uses cookies to ensure you get the best experience on our website.
Learn more
GOT iT!
with us
together we’re making a difference
News Release Details
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026 at 4:05 PM EDT
PDF Version
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $6.50, which was the closing price of Annexon’s common stock on July 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
IR Contact
RSS Feeds
Email Alerts
Contact Us
info@annexonbio.com
650.822.5500
Investors:
investors@annexonbio.com
Media:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
Annexon Biosciences
1400 Sierra Point Parkway,
Building C, 2nd Floor
Brisbane, CA 94005
Privacy Policy
Terms of Use
© 2026 Annexon Inc. All rights reserved.
This website uses cookies to ensure you get the best experience on our website.
Learn more
GOT iT!
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。